Abstract: The present invention relates to sterile pharmaceutical nanoemulsion ophthalmic composition comprising Brinzolamide, Brimonidine and Bimatoprost useful in the treatment of ocular complications such as glaucoma. The nanoemulsion composition of the invention may also comprise in situ gelling composition with or without preservative(s). The invention also relates to processes for making such compositions.

Abstract: The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.

Abstract: The invention relates to topical compositions of lipoglycopeptides. The compositions may additionally contain one or more non-steroidal anti-inflammatory agents. The compositions are used to treat ophthalmic or otic conditions.

Abstract: A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° C., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.

Abstract: A solid pharmaceutical oral composition once or twice daily administration is provided. The composition includes an immediate release core comprising methylergonovine or a pharmaceutically acceptable salt thereof, and a polymer coating disposed on the immediate release core. The composition comprises from about 0.3 mg to about 0.8 mg in total of methylergonovine or a pharmaceutically acceptable salt thereof. The composition is used for treating a subject having a methylergonovine responsive condition such as migraine, refractory migraine, uterine atony, uterine haemorrhage, subinvolution of the uterus, and uterine haemorrhage in the second stage of labor.

Abstract: A solid pharmaceutical oral composition for once or twice daily administration is provided. The composition includes pulsed release pellets. Each pellet includes at least a first drug layer comprising methylergonovine or a pharmaceutically acceptable salt thereof, and a second drug layer comprising methylergonovine or a pharmaceutically acceptable salt thereof. The solid pharmaceutical oral composition includes from about 0.3 mg to about 0.8 mg in total of methylergonovine or a pharmaceutically acceptable salt thereof. The composition is used for treating a subject having a methylergonovine responsive condition such as migraine, refractory migraine, uterine atony, uterine haemorrhage, subinvolution of the uterus, and uterine haemorrhage in the second stage of labor.

Abstract: A solid pharmaceutical oral composition for once daily administration is provided. The composition includes from about 0.5 mg to about 0.8 mg in total of methylergonovine or a pharmaceutically acceptable salt thereof. The composition is used for treating a subject having a methylergonovine responsive condition such as migraine, refractory migraine, uterine atony, uterine haemorrhage, subinvolution of the uterus, and uterine haemorrhage in the second stage of labor.

Abstract: A solid pharmaceutical oral composition for twice daily administration is provided. The composition includes from about 0.3 mg to about 0.6 mg in total of methylergonovine or a pharmaceutically acceptable salt thereof. The composition is used for treating a subject having a methylergonovine responsive condition such as migraine, refractory migraine, uterine atony, uterine haemorrhage, subinvolution of the uterus, and uterine haemorrhage in the second stage of labor.

Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.

Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.

Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.

Abstract: The present invention relates to oral controlled release pharmaceutical compositions comprising Bepotastine. The oral controlled release pharmaceutical composition comprises Bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of Bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused by urticaria.

Abstract: A timed release pharmaceutical composition comprising donepezil is provided wherein the single dose AUC(14-22) of the said composition administered in the morning is about % to about 30% less than the single dose AUC(2-10) of an immediate release composition of donepezil administered in the night, wherein both the compositions have equivalent dose of donepezil.

Abstract: A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° C., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.

Abstract: Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drugs in abnormally high pH environments wherein the extended release layer is formed from a drug resinate of a strong acid ion-exchange resin and a release rate retarding polymer compressed together.

Abstract: The present invention relates to multi component composition of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of multi component composition of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day.

Abstract: The present disclosure provides novel controlled release pharmaceutical dosage form, methods of making the same, and methods of using the same to treat dermatological conditions.

Abstract: Multi-layer solid oral dosage immediate release and extended release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments.

Abstract: Pharmaceutical ophthalmic compositions comprising active ingredient(s) such as carbonic anhydrase inhibitor (CAI) or combinations and processes for making such compositions and the use of these compositions in patient populations including pediatric populations. A process for preparing an ophthalmic composition comprising a carbonic anhydrase inhibitor, which comprises a) preparing a slurry comprising a carbonic anhydrase inhibitor and a surfactant; b) preparing a polymer slurry comprising a polymer and water; c) preparing a solution comprising tonicity and preservative agents; d) mixing the polymer slurry of step b and the solution of step c, to form a vehicle concentrate and adjusting pH; e) adding the slurry of step a, to the vehicle concentrate of step d and mixing to homogenize; f) autoclaving the mixture of step e; g) sizing the mixture of step f, under aseptic condition.

Abstract: A sustained release pharmaceutical composition comprising; a core including memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipients, and a sustained release coating comprising a water insoluble substance and a water soluble substance where the ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3:5:1, optionally containing an immediate release coating having memantine where the immediate release coating is applied over the sustained release coating.